Firstly, B-ALL patients at various CNS infiltration stages were selected for investigation, with CD33, CD34, CD64, CD7, and human leukocyte antigen-D related (HLA-DR) chosen as biomarkers for FCM analysis. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.